Your shopping cart is currently empty

HDAC6-IN-34 (compound 21), an orally active, selective HDAC6 inhibitor, exhibits an IC50 of 18 nM. It enhances tubulin acetylation levels without impacting histone acetylation in cutaneous T-cell lymphoma cells and suppresses TNF-α secretion in LPS-stimulated macrophage cells. Furthermore, HDAC6-IN-34 demonstrates outstanding anti-arthritic efficacy in rats [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 8-10 weeks | 8-10 weeks | |
| 50 mg | $1,980 | 8-10 weeks | 8-10 weeks | |
| 100 mg | $2,500 | 8-10 weeks | 8-10 weeks |
| Description | HDAC6-IN-34 (compound 21), an orally active, selective HDAC6 inhibitor, exhibits an IC50 of 18 nM. It enhances tubulin acetylation levels without impacting histone acetylation in cutaneous T-cell lymphoma cells and suppresses TNF-α secretion in LPS-stimulated macrophage cells. Furthermore, HDAC6-IN-34 demonstrates outstanding anti-arthritic efficacy in rats [1]. |
| Targets&IC50 | HDAC1:3.91 μM, HDAC6:18 nM |
| Molecular Weight | 381.35 |
| Formula | C18H18F3N3O3 |
| Cas No. | 1432508-73-0 |
| Smiles | C(N1C2=C(C(C(F)(F)F)=N1)C(=O)CC(C)(C)C2)C3=CC=C(C(NO)=O)C=C3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.